{"product_id":"managing-persistent-idiopathic-facial-pain-new-international-expert-guidelines-give-hope-to-patients","title":"Managing Persistent Idiopathic Facial Pain: New International Expert Guidelines Give Hope to Patients","description":"\u003cp\u003ePersistent idiopathic facial pain (PIFP) is a rare and poorly understood condition that causes daily facial pain without any identifiable cause. Because there is little high-quality scientific evidence to guide treatment, an international panel of 16 pain experts used a rigorous three-round Delphi consensus process to develop the first internationally agreed-upon recommendations for managing this condition. The experts reached consensus on 35 of 42 statements (83%), strongly emphasizing the importance of a multidisciplinary team approach, avoiding invasive dental and surgical procedures, and measuring treatment success primarily by improved quality of life rather than pain elimination alone.\u003c\/p\u003e\n\n\u003ch1\u003eManaging Persistent Idiopathic Facial Pain: New International Expert Guidelines Give Hope to Patients\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#understanding-pifp\"\u003eUnderstanding Persistent Idiopathic Facial Pain (PIFP)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-research-needed\"\u003eWhy This Research Was Needed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow the Study Was Conducted: A Three-Round Delphi Process\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#expert-panel\"\u003eMeet the Expert Panel\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Where the Experts Agreed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnostic-recommendations\"\u003eDiagnostic Recommendations: How PIFP Should Be Evaluated\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#differential-diagnoses\"\u003eDifferential Diagnoses: What Else Must Be Ruled Out\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment-recommendations\"\u003eTreatment Recommendations: A Multidisciplinary Approach\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#medication-recommendations\"\u003eMedication Recommendations: The Step-by-Step Approach\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#procedures-to-avoid\"\u003eProcedures to Avoid: Why Less Invasive Is Better\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#follow-up-care\"\u003eFollow-Up Care: Individualized and Ongoing\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment-success\"\u003eDefining Treatment Success: Quality of Life Comes First\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#patient-recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePIFP is a rare, chronic facial pain without identifiable cause, affecting about 3 in 10,000 people, mostly women.\u003c\/li\u003e\n\u003cli\u003eAn international panel of 16 pain experts reached consensus on 35 of 42 statements (83%) using a three-round Delphi process.\u003c\/li\u003e\n\u003cli\u003eInvasive dental and surgical procedures should be avoided in PIFP unless a definite local cause is found.\u003c\/li\u003e\n\u003cli\u003eTreatment should be multidisciplinary, with first-line tricyclic antidepressants, then SNRIs, gabapentinoids, or botulinum toxin; opioids are discouraged.\u003c\/li\u003e\n\u003cli\u003eTreatment success is defined by improved quality of life and tolerable pain, not by complete pain elimination.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"understanding-pifp\"\u003eUnderstanding Persistent Idiopathic Facial Pain (PIFP)\u003c\/h2\u003e\n\n\u003cp\u003ePersistent idiopathic facial pain, also known by its older name \"atypical facial pain,\" is a chronic pain condition that affects the face. It was formally renamed in the 3rd edition of the International Classification of Headache Disorders (ICHD) in 2018 and recognized in the first International Classification of Orofacial Pain (ICOP) in 2020.\u003c\/p\u003e\n\n\u003cp\u003eThe condition is defined as \"persistent facial pain, with variable features, recurring daily for more than 2 hours per day for more than three months, in the absence of clinical neurological deficit or preceding causative event.\" In simple terms, patients have daily facial pain that lasts for months or years, and despite thorough testing, no medical or dental cause can be found.\u003c\/p\u003e\n\n\u003cp\u003ePIFP is rare, with a lifetime prevalence of approximately \u003cstrong\u003e0.03%\u003c\/strong\u003e. To put that in perspective, only about 3 out of every 10,000 people will experience this condition during their lifetime. It should not be confused with persistent idiopathic dentoalveolar pain (PIDAP), which is pain perceived specifically within the teeth and gums (intraoral tissues). PIFP can only be diagnosed when no other condition can explain the pain.\u003c\/p\u003e\n\n\u003cp\u003eThe majority of patients with PIFP are women. They typically describe the pain as \u003cstrong\u003ediffuse, dull, aching, or nagging\u003c\/strong\u003e — and importantly, the pain does not follow the distribution of any specific nerve in the face. This is a key clinical distinction from neuropathic pain conditions like trigeminal neuralgia, which affects specific nerve pathways. The pain can be both deep and superficial, and it is often described as refractory (difficult to treat) and persisting for many years.\u003c\/p\u003e\n\n\u003ch2 id=\"why-research-needed\"\u003eWhy This Research Was Needed\u003c\/h2\u003e\n\n\u003cp\u003eFacial pain in general is very common. Orofacial pain (pain confined to the oral cavity and\/or face) affects approximately \u003cstrong\u003e16–22% of the population\u003c\/strong\u003e, and it has a major impact on quality of life, often causing impaired sleep, mood disturbances, and considerable disability. Dental pain is the most common form of orofacial pain, followed by pain linked to temporomandibular disorders (TMD), which involve the jaw joint and chewing muscles.\u003c\/p\u003e\n\n\u003cp\u003eThe underlying cause of PIFP remains unknown. Researchers have suggested that the pain may involve a disproportionate response to a minor injury, and brain imaging studies point toward \u003cstrong\u003ecentral sensitization\u003c\/strong\u003e — a process in which the central nervous system becomes overly sensitive to pain signals. PIFP may also be considered a \u003cstrong\u003enociplastic pain\u003c\/strong\u003e type, which arises from altered pain processing in the central nervous system rather than from identifiable tissue damage or nerve injury.\u003c\/p\u003e\n\n\u003cp\u003eDespite these insights, there was previously no established protocol for managing PIFP. Many different treatments have been proposed, but the lack of high-quality randomized controlled trials (the gold standard of medical evidence) has made evidence-based treatment decisions extremely difficult. As with many chronic pain conditions, a multimodal approach — combining multiple treatment strategies — has been recommended, ideally delivered by an interdisciplinary or transdisciplinary team with a joint treatment plan.\u003c\/p\u003e\n\n\u003cp\u003eIn the absence of scientific evidence, healthcare providers must rely on clinical experience. The collective experience of many experts, summarized into a consensus, is considered more valuable than the experience of any single individual. This is exactly what this Delphi study set out to achieve: \u003cstrong\u003eestablishing international consensus-derived guidelines for the management of patients with PIFP\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow the Study Was Conducted: A Three-Round Delphi Process\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers used the classic Delphi consensus method, a well-established technique for gathering expert opinions. One of the key advantages of the Delphi method is that it maintains \u003cstrong\u003eanonymity among experts\u003c\/strong\u003e, eliminating the social pressure and influence that can occur when people meet face-to-face. This allows participants to express their true opinions freely.\u003c\/p\u003e\n\n\u003cp\u003eThe study protocol was registered on Researchweb Region Uppsala and publicly presented in the Uppsala Public Dental Health Service's 2022 Odontology Research Report.\u003c\/p\u003e\n\n\u003cp\u003eThe Delphi process consisted of three rounds, all conducted in English:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRound 1 (Open-Ended Questions):\u003c\/strong\u003e The three lead authors created a questionnaire with 10 open-ended questions focused on the management of PIFP. Experts were instructed to freely express their opinions. The free-text responses were then analyzed using Malterud's systematic text condensation method — a rigorous qualitative analysis technique involving four phases: reading to gain overall understanding, identifying and coding meaning units, condensing the data into artificial quotations, and synthesizing the results into statements.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRound 2 (Quantitative Questionnaire):\u003c\/strong\u003e The qualitative analysis produced a quantitative questionnaire with \u003cstrong\u003e42 statements\u003c\/strong\u003e. Experts responded to each statement using a five-item Likert scale ranging from \"strongly agree\" to \"strongly disagree.\" They could also provide free-text comments for each statement. After this round, each expert received a summary of the group's responses, allowing them to compare their opinions with others'. Minor wording changes were made to nine statements to clarify their meaning based on feedback.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRound 3 (Refined Questionnaire):\u003c\/strong\u003e The experts received the refined 42-statement questionnaire for a final round. Afterward, they received another summary of responses and could correct any errors. The study was then closed, and the results were analyzed and extensively discussed by the expert panel and lead authors.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eA maximum of two reminders were sent to experts who did not respond to the web-based questionnaires. The response rate was \u003cstrong\u003e100% in all rounds\u003c\/strong\u003e — meaning every single expert completed every round of the study.\u003c\/p\u003e\n\n\u003cp\u003eConsensus was defined as \u003cstrong\u003emore than 80% agreement or disagreement\u003c\/strong\u003e among the experts, meaning at least 13 out of the 16 experts had to agree or disagree for consensus to be reached. A secondary threshold was also established: if 11–12 experts (68–75%) agreed or disagreed, consensus was not reached, but a \u003cstrong\u003emajority opinion\u003c\/strong\u003e was considered to exist.\u003c\/p\u003e\n\n\u003ch2 id=\"expert-panel\"\u003eMeet the Expert Panel\u003c\/h2\u003e\n\n\u003cp\u003eEighteen international pain experts were invited to participate. An expert was defined as a researcher with identifiable peer-reviewed publications and at least \u003cstrong\u003e10 years of clinical experience\u003c\/strong\u003e in managing pain patients. The mean total number of peer-reviewed publications among the expert panel was \u003cstrong\u003e226\u003c\/strong\u003e (range: 45–608).\u003c\/p\u003e\n\n\u003cp\u003eTwo experts declined due to time constraints, leaving \u003cstrong\u003e16 experts from 3 of the 6 WHO regions\u003c\/strong\u003e (the European Region, the Region of the Americas, and the Western Pacific Region). The panel spanned a remarkable range of specialties:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eNeurology\u003c\/li\u003e\n  \u003cli\u003eNeurosurgery\u003c\/li\u003e\n  \u003cli\u003eNeurophysiology\u003c\/li\u003e\n  \u003cli\u003eHeadache medicine\u003c\/li\u003e\n  \u003cli\u003ePain management\u003c\/li\u003e\n  \u003cli\u003eOrofacial pain\u003c\/li\u003e\n  \u003cli\u003eEndodontics (root canal treatment specialty)\u003c\/li\u003e\n  \u003cli\u003eOral and maxillofacial surgery\u003c\/li\u003e\n  \u003cli\u003eOral medicine\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe experts came from 10 countries: Israel, Brazil, the UK, Canada, Japan, Sweden, Germany, Greece, the USA, and Switzerland. The panel included a mix of dentists and physicians, reflecting the interdisciplinary nature of facial pain care. The three lead authors (Erik Lindfors, Per Alstergren, and Torsten Gordh) did not participate as members of the expert panel to avoid influencing the results. Experts received no financial compensation, but were invited to serve as co-authors on the publication.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Where the Experts Agreed\u003c\/h2\u003e\n\n\u003cp\u003eThe results of the study were clear and striking. Of the 42 statements presented to the experts:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e35 out of 42 statements (83%)\u003c\/strong\u003e reached full consensus\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3 statements (7%)\u003c\/strong\u003e achieved majority agreement (68–75% of experts agreed but did not reach the 80% consensus threshold)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4 statements (10%)\u003c\/strong\u003e achieved neither consensus nor majority agreement\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe findings emphasized two overarching themes: \u003cstrong\u003emultidisciplinary collaboration\u003c\/strong\u003e and \u003cstrong\u003eavoidance of invasive procedures\u003c\/strong\u003e. These two principles emerged as the cornerstone of PIFP management.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnostic-recommendations\"\u003eDiagnostic Recommendations: How PIFP Should Be Evaluated\u003c\/h2\u003e\n\n\u003cp\u003eThe experts reached consensus on a comprehensive, step-by-step diagnostic approach. This is crucial because PIFP is a \u003cem\u003ediagnosis of exclusion\u003c\/em\u003e — meaning every other possible cause of the pain must be ruled out before the diagnosis can be made.\u003c\/p\u003e\n\n\u003ch3\u003eHistory Taking (Anamnestic Data)\u003c\/h3\u003e\n\n\u003cp\u003eThe experts emphasized that several pieces of information in the patient's history and symptom report are important for diagnosing PIFP:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePsychosocial history\u003c\/strong\u003e — stress, mental health disorders such as depression and anxiety, are important historical data\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComorbid pain conditions\u003c\/strong\u003e — different types of headaches and other persistent pain conditions elsewhere in the body should be considered\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOther persistent pain sites\u003c\/strong\u003e — information about generalized pain conditions is relevant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNerve lesion findings\u003c\/strong\u003e — if history and clinical findings point toward nerve damage (neuropathic pain), this \u003cem\u003econtradicts\u003c\/em\u003e a PIFP diagnosis\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrior minor procedures\u003c\/strong\u003e — patients with PIFP may report minor surgery or injury to the face, jaw, teeth, or gums, but upon clinical and radiographic examination, no local pathology is found to explain the pain\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eClinical Examination\u003c\/h3\u003e\n\n\u003cp\u003eSeveral examination steps were considered essential by the expert panel:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInitial dental examination\u003c\/strong\u003e to rule out dental pathology is \u003cstrong\u003emandatory\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQualitative somatosensory examination\u003c\/strong\u003e of the painful area (testing touch, temperature, and pinprick sensation) is an important diagnostic procedure\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuantitative sensory testing (QST)\u003c\/strong\u003e — which measures sensory thresholds in a standardized way — can be indicated in some cases based on the results of the qualitative examination\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNeurological examination of the cranial nerves\u003c\/strong\u003e is important\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNerve conduction tests\u003c\/strong\u003e can be warranted in some cases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTemporomandibular disorder (TMD) examination\u003c\/strong\u003e, preferably performed by a dentist specialized in orofacial pain, is an important part of the diagnostic process\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePsychological assessment\u003c\/strong\u003e — patients with suspected PIFP must be assessed for anxiety, depression, post-traumatic stress disorder (PTSD), and pain catastrophizing (a pattern of negative thinking about pain)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiagnostic blocks\u003c\/strong\u003e with local anesthetics can be valuable for categorizing the pain\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eImaging Recommendations\u003c\/h3\u003e\n\n\u003cp\u003eThe experts reached consensus on the following imaging approach:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiology of the orofacial region is usually necessary\u003c\/strong\u003e to rule out local pathology\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntraoral and\/or panoramic radiographs are mandatory\u003c\/strong\u003e to rule out dental pathology (panoramic radiographs show both jaws and all teeth in a single image)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComputed tomography (CT) or cone-beam computed tomography (CBCT)\u003c\/strong\u003e of the teeth, jaws, and facial structures are helpful in the diagnostic process\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHead magnetic resonance imaging (MRI)\u003c\/strong\u003e may be necessary depending on symptoms, to rule out malignancy (cancer) or intracranial (inside-the-skull) processes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"differential-diagnoses\"\u003eDifferential Diagnoses: What Else Must Be Ruled Out\u003c\/h2\u003e\n\n\u003cp\u003eThe experts identified \u003cstrong\u003efive major differential diagnoses\u003c\/strong\u003e that must be excluded in any patient with suspected PIFP:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNeuropathic pain\u003c\/strong\u003e — including post-traumatic neuropathic pain or trigeminal neuralgia (a condition causing severe, electric-shock-like facial pain)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePain of dental origin\u003c\/strong\u003e — such as tooth decay, abscess, or cracked teeth\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTMD pain\u003c\/strong\u003e — including pain referred from the neck\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrimary headaches\u003c\/strong\u003e — such as migraine or tension-type headaches\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMalignancy\u003c\/strong\u003e — cancer in the facial region or cancer elsewhere in the body that refers pain to the face\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn addition, the experts identified several other differential diagnoses of interest:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eEar, nose, and throat (ENT) pathology\u003c\/li\u003e\n  \u003cli\u003eTemporal arteritis (a type of blood vessel inflammation affecting the temples)\u003c\/li\u003e\n  \u003cli\u003eOsteomyelitis of the jaw (a bone infection)\u003c\/li\u003e\n  \u003cli\u003eChronic widespread pain conditions\u003c\/li\u003e\n  \u003cli\u003eLyme disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"treatment-recommendations\"\u003eTreatment Recommendations: A Multidisciplinary Approach\u003c\/h2\u003e\n\n\u003cp\u003eThe experts strongly endorsed a multidisciplinary approach to treating PIFP. The investigation and examination of a patient with suspected PIFP should be multidisciplinary and include a dental examination to exclude dental pathology. If possible, a dentist specialized in orofacial pain should also be consulted. Important medical specialties in the multidisciplinary investigation include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eNeurologists\u003c\/li\u003e\n  \u003cli\u003ePsychologists or psychiatrists\u003c\/li\u003e\n  \u003cli\u003eEar, nose, and throat (ENT) specialists\u003c\/li\u003e\n  \u003cli\u003ePhysicians specialized in pain medicine\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA physiotherapist specialized in head\/neck pain is desirable if available.\u003c\/p\u003e\n\n\u003cp\u003eNon-pharmacological treatments were strongly emphasized:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient education\u003c\/strong\u003e about chronic pain and \u003cstrong\u003ebehavior therapy such as cognitive behavioral therapy (CBT)\u003c\/strong\u003e are \"very important interventions\" in managing PIFP according to the expert consensus\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeneral well-being factors\u003c\/strong\u003e — including sleep, exercise, and diet — should be a focus of treatment\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultimodal pain management programs\u003c\/strong\u003e can be useful in some cases to help patients cope with chronic pain\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"medication-recommendations\"\u003eMedication Recommendations: The Step-by-Step Approach\u003c\/h2\u003e\n\n\u003cp\u003eThe experts reached consensus on a specific, step-by-step pharmacological treatment approach, which can be thought of as a ladder:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFirst-line treatment:\u003c\/strong\u003e Tricyclic antidepressants (TCAs) — specifically \u003cstrong\u003eAmitriptyline or Nortriptyline\u003c\/strong\u003e. These medications, originally developed as antidepressants, are widely used for chronic pain because they affect pain-signaling pathways in the brain and spinal cord.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf TCAs are not well tolerated:\u003c\/strong\u003e A serotonin-norepinephrine reuptake inhibitor (SNRI) such as \u003cstrong\u003eDuloxetine or Venlafaxine\u003c\/strong\u003e can be considered. SNRIs also work on pain pathways in the central nervous system and typically have a different side effect profile than TCAs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf the effect of TCA or SNRI is insufficient:\u003c\/strong\u003e A switch to, or combination with, a \u003cstrong\u003egabapentinoid\u003c\/strong\u003e such as \u003cstrong\u003eGabapentin or Pregabalin\u003c\/strong\u003e can be considered. These medications are commonly used for nerve-related pain.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThird-line treatment:\u003c\/strong\u003e \u003cstrong\u003eSubcutaneous Botulinum toxin type A injections\u003c\/strong\u003e (Botox) might be an option.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eCritically, the experts agreed that \u003cstrong\u003eopioids should in general be avoided\u003c\/strong\u003e in patients with PIFP. This is consistent with broader guidelines for chronic pain, which caution against opioids due to risks of dependence, tolerance, and limited long-term effectiveness. Pharmacological treatment should be used \"if this option has not already been exhausted.\"\u003c\/p\u003e\n\n\u003ch2 id=\"procedures-to-avoid\"\u003eProcedures to Avoid: Why Less Invasive Is Better\u003c\/h2\u003e\n\n\u003cp\u003eOne of the strongest messages from this study is the harm that can come from unnecessary invasive procedures. The experts reached a clear consensus: \u003cstrong\u003einvasive and irreversible dental and surgical procedures without a definite indication should be avoided\u003c\/strong\u003e due to the risk of increased pain and a deteriorated clinical situation.\u003c\/p\u003e\n\n\u003cp\u003eSpecifically, the following procedures should be avoided unless there is strong, definite evidence of a local cause or pathology:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eRoot canal treatment\u003c\/li\u003e\n  \u003cli\u003eApical surgery (surgery at the tip of a tooth root)\u003c\/li\u003e\n  \u003cli\u003eTooth extraction\u003c\/li\u003e\n  \u003cli\u003eOcclusal equilibration (reshaping the biting surfaces of teeth)\u003c\/li\u003e\n  \u003cli\u003eOral prosthetic treatment (crowns, bridges, etc.)\u003c\/li\u003e\n  \u003cli\u003eOrthognathic surgery (jaw surgery)\u003c\/li\u003e\n  \u003cli\u003eExploratory surgery (surgery performed to look for a problem without a clear target)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis recommendation reflects the unfortunate reality that many PIFP patients undergo repeated dental procedures — often multiple extractions or root canals — in an attempt to relieve pain that ultimately has no dental cause. These procedures frequently make the pain worse and can lead to permanent changes in the mouth that create additional problems.\u003c\/p\u003e\n\n\u003ch2 id=\"follow-up-care\"\u003eFollow-Up Care: Individualized and Ongoing\u003c\/h2\u003e\n\n\u003cp\u003eThe experts agreed that follow-up should always be \u003cstrong\u003eindividualized\u003c\/strong\u003e, since it depends on numerous factors, including:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe type of treatment engaged (pharmacological treatment, behavior therapy, pain management program, etc.)\u003c\/li\u003e\n  \u003cli\u003ePotential adverse effects of treatment\u003c\/li\u003e\n  \u003cli\u003eThe expected time course of the treatment being given\u003c\/li\u003e\n  \u003cli\u003ePatient adherence to treatment\u003c\/li\u003e\n  \u003cli\u003ePatient-related issues (such as sense of security and the need to be taken seriously)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn general, follow-up visits should be \u003cstrong\u003emore frequent at the beginning\u003c\/strong\u003e of the treatment regimen and should continue on a regular basis over a period decided by the leading specialist in joint agreement with the patient.\u003c\/p\u003e\n\n\u003cp\u003eBecause PIFP is a chronic condition, the experts emphasized that it is important for the patient to have a \u003cstrong\u003econtact person\u003c\/strong\u003e (for example, the leading specialist) for when they need support, and that the complaints and concerns of the patient must be taken seriously.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment-success\"\u003eDefining Treatment Success: Quality of Life Comes First\u003c\/h2\u003e\n\n\u003cp\u003ePerhaps the most important philosophical shift in these guidelines is how treatment success is measured. The experts reached a clear consensus that:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe most important measure of treatment success is increased quality of life and well-being\u003c\/strong\u003e, including return to daily activities such as work, social activities, and family life\u003c\/li\u003e\n  \u003cli\u003eAnother measure of treatment success is \u003cstrong\u003epain reduction to a tolerable level\u003c\/strong\u003e that the patient can accept\u003c\/li\u003e\n  \u003cli\u003eIf pain relief cannot be accomplished, \u003cstrong\u003eincreased quality of life can still be achieved through increased acceptance and coping strategies\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, the experts did \u003cem\u003enot\u003c\/em\u003e reach consensus on using specific pain intensity reduction thresholds as measures of treatment success. Statements proposing that a \u003cstrong\u003e30% pain reduction\u003c\/strong\u003e on a Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) constitutes treatment success, or that a \u003cstrong\u003e50% pain reduction\u003c\/strong\u003e constitutes success, both failed to achieve consensus. This suggests that the experts view treatment success in PIFP as a more holistic concept than simply a number on a pain scale.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThese international consensus guidelines represent a major step forward for patients with PIFP. For the first time, there is an internationally agreed-upon framework for how these patients should be evaluated and managed.\u003c\/p\u003e\n\n\u003cp\u003eThe key takeaways for patient care are:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePIFP requires a team approach.\u003c\/strong\u003e No single specialist can manage PIFP alone. The ideal team includes a dentist specialized in orofacial pain, a neurologist, a pain physician, a psychologist or psychiatrist, and sometimes a physiotherapist and ENT specialist.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtection from unnecessary procedures.\u003c\/strong\u003e The strong consensus against invasive dental and surgical procedures protects patients from treatments that are unlikely to help and can make the pain worse.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvidence-informed medication choices.\u003c\/strong\u003e The recommended medication ladder (TCA → SNRI → gabapentinoid → botulinum toxin) provides clear guidance for healthcare providers, while the warning against opioids protects patients from potentially harmful medications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuality of life is the ultimate goal.\u003c\/strong\u003e Even when complete pain relief is not possible, patients can achieve meaningful improvement in their quality of life through acceptance, coping strategies, and behavioral therapies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Study\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand the limitations of this study when interpreting its findings:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsensus is not the same as evidence.\u003c\/strong\u003e While the Delphi method harnesses the collective expertise of international specialists, the recommendations are based on expert opinion rather than randomized controlled trials. The authors acknowledge this and describe their work as \"a first step in gathering knowledge for future evidence-based guidelines and more specific treatment recommendations.\"\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeographic limitations.\u003c\/strong\u003e The expert panel included participants from only 3 of the 6 WHO regions (Europe, the Americas, and the Western Pacific). No experts came from the African, Eastern Mediterranean, or South-East Asian regions, which may limit the global applicability of these guidelines.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited diversity in pain management settings.\u003c\/strong\u003e All experts practice in high-income healthcare systems, which may not reflect the resources and care structures available in other parts of the world.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe four statements without consensus.\u003c\/strong\u003e For 4 out of 42 statements (10%), neither consensus nor majority agreement was reached. This underscores that some aspects of PIFP management remain genuinely controversial, even among experts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"patient-recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you or a loved one has been diagnosed with persistent idiopathic facial pain, here is what these guidelines mean in practical terms:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek a multidisciplinary team.\u003c\/strong\u003e Ask your doctor for a referral to an orofacial pain specialist and, if possible, a pain management clinic that offers a team-based approach. Ideally, your care team should include a dentist experienced in orofacial pain, a neurologist, and a pain physician.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThink carefully before dental procedures.\u003c\/strong\u003e Unless there is clear evidence of a dental problem (such as a cracked tooth or infection), avoid root canals, extractions, and other invasive dental procedures. These procedures rarely help PIFP and can make the pain worse.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe patient with medication trials.\u003c\/strong\u003e The recommended medications (amitriptyline, nortriptyline, duloxetine, venlafaxine, gabapentin, pregabalin) may take several weeks or months to show benefit. It is common to need to try more than one medication before finding what works for you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about non-drug treatments.\u003c\/strong\u003e Cognitive behavioral therapy (CBT), patient education, physiotherapy, and multimodal pain management programs are strongly recommended by the experts. These approaches can help you develop coping strategies that improve your quality of life even if pain persists.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFocus on quality of life.\u003c\/strong\u003e The ultimate goal of treatment is not necessarily complete pain elimination — it is helping you return to work, social activities, and family life. Discuss quality-of-life goals with your healthcare provider.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoid opioids.\u003c\/strong\u003e Unless prescribed by a specialist for severe, short-term needs, opioids should generally be avoided for PIFP due to limited long-term effectiveness and risks of dependence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKeep a contact person.\u003c\/strong\u003e Make sure you have a designated healthcare provider you can contact when needed, and don't hesitate to raise concerns — the guidelines emphasize that patients' complaints must be taken seriously.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThese guidelines are not a guarantee of a specific outcome, but they represent the best collective thinking of 16 of the world's foremost experts in facial pain. They offer patients a roadmap toward better management — one that prioritizes safety, compassion, and the things that matter most to patients in their daily lives.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is persistent idiopathic facial pain (PIFP)?\u003c\/h3\u003e\n\u003cp\u003ePIFP is a rare chronic pain condition causing daily facial pain for more than three months, with no identifiable medical or dental cause. It affects about 3 in 10,000 people, mostly women. The pain is often dull or aching and does not follow a specific nerve pathway.\u003c\/p\u003e\n\u003ch3\u003eHow is PIFP diagnosed?\u003c\/h3\u003e\n\u003cp\u003ePIFP is a diagnosis of exclusion. Doctors take a detailed history, perform dental, neurological, and sensory exams, and use imaging like dental X-rays, CT, or MRI to rule out other causes. Psychological assessment is also recommended. Five major conditions must be ruled out: neuropathic pain, dental pain, jaw joint pain, headaches, and cancer.\u003c\/p\u003e\n\u003ch3\u003eWhat treatments are recommended for PIFP?\u003c\/h3\u003e\n\u003cp\u003eA multidisciplinary team approach is strongly recommended, including an orofacial pain dentist, neurologist, pain specialist, and psychologist. Non-drug treatments like patient education, cognitive behavioral therapy, and attention to sleep, exercise, and diet are considered very important. Medication may also be used, but invasive dental or surgical procedures should be avoided.\u003c\/p\u003e\n\u003ch3\u003eShould I avoid dental procedures for PIFP?\u003c\/h3\u003e\n\u003cp\u003eYes. The expert consensus strongly advises avoiding invasive and irreversible dental and surgical procedures—such as root canals, tooth extractions, jaw surgery, or exploratory surgery—unless there is clear evidence of a local cause. These procedures can increase pain and worsen your condition. Always seek an orofacial pain specialist before considering such treatments.\u003c\/p\u003e\n\u003ch3\u003eWhat medications are used for PIFP?\u003c\/h3\u003e\n\u003cp\u003eExperts recommend a step-by-step approach. First-line are tricyclic antidepressants like amitriptyline or nortriptyline. If these are not tolerated, an SNRI such as duloxetine or venlafaxine may help. Gabapentin or pregabalin can be added or switched. Botulinum toxin injections are a third-line option. Opioids should generally be avoided.\u003c\/p\u003e\n\u003ch3\u003eHow is treatment success measured in PIFP?\u003c\/h3\u003e\n\u003cp\u003eTreatment success is measured primarily by improved quality of life and well-being, including return to daily activities like work and social life. Pain reduction to a tolerable level is also a goal, but complete pain elimination is not required. Experts did not agree on using specific pain scale reduction percentages to define success.\u003c\/p\u003e\n\u003ch3\u003eWhat should I do if I have PIFP?\u003c\/h3\u003e\n\u003cp\u003eSeek a multidisciplinary team. Ask for referrals to an orofacial pain specialist and a pain management clinic. Be cautious about dental procedures, be patient with medication trials, and ask about cognitive behavioral therapy. Focus on quality-of-life goals. Avoid opioids unless a specialist prescribes them for short-term severe needs, and keep a designated contact person.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Management of persistent idiopathic facial pain\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e \u003ca href=\"https:\/\/doi.org\/10.1177\/03331024251399927\" target=\"_blank\" rel=\"noopener\"\u003e10.1177\/03331024251399927\u003c\/a\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Erik Lindfors, Per Alstergren, Rafael Benoliel, Paulo Conti, Justin Durham, Jean-Paul Goulet, Osamu Komiyama, Thomas List, Arne May, Dimos-Dimitrios Mitsikostas, Donald R. Nixdorf, Maria Pigg, Tara Renton, Gunnar Skagerberg, Peter Svensson, Rolf-Detlef Treede, Jens Christoph Türp, Joanna M. Zakrzewska, and Torsten Gordh\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Cephalalgia, 2025, Vol. 45(12), pages 1–17. Published by the International Headache Society.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1177\/03331024251399927\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDate Received:\u003c\/strong\u003e 7 June 2025; \u003cstrong\u003eRevised:\u003c\/strong\u003e 23 October 2025; \u003cstrong\u003eAccepted:\u003c\/strong\u003e 24 October 2025\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy Registration:\u003c\/strong\u003e The study protocol was registered on Researchweb Region Uppsala and publicly presented in the Uppsala Public Dental Health Service's 2022 Odontology Research Report. The research was conducted under a Creative Commons Attribution 4.0 License.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It has been written to make the study's findings accessible to patients and their families, but it does not replace professional medical advice. Always consult a qualified healthcare provider about your specific condition and treatment options.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400024670364,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.es\/products\/managing-persistent-idiopathic-facial-pain-new-international-expert-guidelines-give-hope-to-patients","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}